Search results for "hemic and immune systems"

showing 10 items of 340 documents

A mesoscopic approach to radiation-induced defect aggregation in alkali halides stimulated by the elastic interaction of mobile Frenkel defects

1994

The radiation-induced aggregation of Frenkel defects in alkali halides is studied in terms of a mesoscopic approach. The asymmetry in elastic interactions between mobile interstitials (I–I) and bet...

Mesoscopic physicsPhysics and Astronomy (miscellaneous)Chemistrymedia_common.quotation_subjectMetals and AlloysHalideMineralogyIonic crystalchemical and pharmacologic phenomenahemic and immune systemsRadiation inducedCondensed Matter PhysicsAlkali metalAsymmetryElectronic Optical and Magnetic MaterialsChemical physicsGeneral Materials Sciencemedia_commonPhilosophical Magazine A
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

2019

Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent. Several studies have shown that a greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and higher survival rate. Patients and Methods: We investigated by enzyme-linked immunosorbent assay (ELISA) the correlation between PD-1 levels in plasma and the presence/absence of TILs in 28 patients with metastatic melanoma. Results: Low plasma PD-1 levels were correlated with brisk TILs in primary melanoma, whereas intermediate values correlated with the nonbrisk TILs, and hig…

Metastatic melanoma[SDV]Life Sciences [q-bio]plasma PD-1chemical and pharmacologic phenomena[SDV.BC]Life Sciences [q-bio]/Cellular Biologylcsh:RC254-282immune response03 medical and health sciences0302 clinical medicineImmune systembrisk TILmelanomaMedicineIn patientOriginal Researchplasma PD-L1030304 developmental biology0303 health sciencesTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebrisk TILs3. Good healthOncologytumor-infiltrating lymphocytes030220 oncology & carcinogenesisCancer researchbusinesshuman activitiesTherapeutic Advances in Medical Oncology
researchProduct

Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR…

2002

ABSTRACTAntigen-specific T-cell responses may be described by combining three categories: (i) the specificity and effector functions of a T-cell population, (ii) the quantity of T-cell responses (i.e., the number of responding T cells within the CD4/CD8 population), and (iii) the “quality” of T cells (defined by the T-cell receptor [TCR] structure). Several methods to measure T-cell responses are now available including evaluation of T-cell precursors using limiting dilution, the enzyme-linked immunospot assay, ex vivo TCR variable (v)-segment analysis determined by flow cytometry, and TCR-CDR3 length analysis (spectratyping), as well as identification of peptide-specific T cells using majo…

Microbiology (medical)CD4-Positive T-LymphocytesReceptors Antigen T-Cell alpha-betaClinical BiochemistryImmunologyPopulationchemical and pharmacologic phenomenaComplementarity determining regionCD8-Positive T-LymphocytesMajor histocompatibility complexCDR3 SpectratypingFlow cytometryNeoplasmsCellular ImmunologymedicineImmunology and AllergyHumanseducationeducation.field_of_studybiologymedicine.diagnostic_testT-cell receptorhemic and immune systemsFlow CytometryMolecular biologyComplementarity Determining RegionsImmunologybiology.proteinAntibodyCD8Clinical and diagnostic laboratory immunology
researchProduct

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

2004

Fms-like tyrosine kinase 3 (FLT3) receptor mutations as internal tandem duplication (ITD) or within the kinase domain are detected in up to 35% of patients with acute myeloid leukemia (AML). N-benzoyl staurosporine (PKC412), a highly effective inhibitor of mutated FLT3 receptors, has significant antileukemic efficacy in patients with FLT3-mutated AML. Mutation screening of FLT3 exon 20 in AML patients (n = 110) revealed 2 patients with a novel mutation (Y842C) within the highly conserved activation loop of FLT3. FLT3-Y842C-transfected 32D cells showed constitutive FLT3 tyrosine phosphorylation and interleukin 3 (IL-3)-independent growth. Treatment with PKC412 led to inhibition of proliferat…

Models MolecularImmunologyBiologymedicine.disease_causeBiochemistryCell Linechemistry.chemical_compoundMicefluids and secretionshemic and lymphatic diseasesProto-Oncogene ProteinsmedicineSTAT5 Transcription FactorAnimalsHumansTyrosinePhosphotyrosineMutationCell CycleMyeloid leukemiaReceptor Protein-Tyrosine Kinaseshemic and immune systemsTyrosine phosphorylationCell BiologyHematologymedicine.diseaseMilk ProteinsProtein Structure TertiaryDNA-Binding ProteinsEnzyme ActivationLeukemiaLeukemia Myeloid AcutechemistryGene Expression Regulationfms-Like Tyrosine Kinase 3embryonic structuresFms-Like Tyrosine Kinase 3MutationCancer researchTrans-ActivatorsTyrosineSignal transductionTyrosine kinaseSignal TransductionBlood
researchProduct

Complete subunit sequences, structure and evolution of the 6 x 6-mer hemocyanin from the common house centipede, Scutigera coleoptrata.

2003

Hemocyanins are large oligomeric copper-containing proteins that serve for the transport of oxygen in many arthropod species. While studied in detail in the Chelicerata and Crustacea, hemocyanins had long been considered unnecessary in the Myriapoda. Here we report the complete molecular structure of the hemocyanin from the common house centipede Scutigera coleoptrata (Myriapoda: Chilopoda), as deduced from 2D-gel electrophoresis, MALDI-TOF mass spectrometry, protein and cDNA sequencing, and homology modeling. This is the first myriapod hemocyanin to be fully sequenced, and allows the investigation of hemocyanin structure-function relationship and evolution. S. coleoptrata hemocyanin is a 6…

Models MolecularProtein Conformationmedicine.medical_treatmentMolecular Sequence DataMyriapodachemical and pharmacologic phenomenaBiochemistryEvolution MolecularMonophylymedicineAnimalsAmino Acid SequenceCloning MolecularArthropodsPhylogenybiologyMandibulatahemic and immune systemsHemocyaninAnatomybiology.organism_classificationProtein SubunitsEvolutionary biologyHemocyaninsChelicerataArthropodCentipedeSequence AlignmentScutigera coleoptrataEuropean journal of biochemistry
researchProduct

Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin.

2003

The CD95 (Fas/APO-1) linkage to the actin cytoskeleton through ezrin is an essential requirement for susceptibility to the CD95-mediated apoptosis in CD4+ T cells. We have previously shown that moesin was not involved in the binding to CD95. Here we further support the specificity of the ezrin/CD95 binding, showing that radixin did not bind CD95. The ezrin region specifically and directly involved in the binding to CD95 was located in the middle lobe of the ezrin FERM domain, between amino acids 149 and 168. In this region, ezrin, radixin, and moesin show 60-65% identity, as compared with the 86% identity in the whole FERM domain. Transfection of two different human cell lines with a green …

Moesinchemical and pharmacologic phenomenaApoptosismacromolecular substancesBiologyBiochemistryEzrinRadixinhemic and lymphatic diseasesHumansfas ReceptorMolecular BiologyActinBinding SitesFERM domainhemic and immune systemsCell BiologyTransfectionActin cytoskeletonPhosphoproteinsActinsCell biologyProtein Structure TertiaryCytoskeletal ProteinsMutationbiological phenomena cell phenomena and immunityBinding domainHeLa CellsProtein BindingSignal TransductionThe Journal of biological chemistry
researchProduct

Zinc oxide nanorod based immunosensing platform for the determination of human leukemic cells.

2019

Zinc oxide (ZnO) based nanostructures owing unique physical properties – high photoluminescence, bio- compatibility and other characteristics, therefore, they attract attention as building blocks suitable for biosensor development. In this research as a target we have used human leukemic cell line IM9 (IM9). IM9 was derived from the patient with a multiple myeloma and expressed cluster of differentiation proteins СD19 on the surface of 85–95% here investigated cancer cells. As a control sample healthy human's peripheral blood mononuclear cells (PBMC) were used and the expression of CD19 protein was found only in 5–9% of these cells. Two types of antibodies labeled by f…

Monoclonal antibodymedicine.drug_class02 engineering and technologyCell SeparationMonoclonal antibody01 natural sciencesCD19Analytical ChemistryFlow cytometrychemistry.chemical_compoundHuman lymphocytesmedicineHumansFlow cytometryZnO-nanorodsFluorescein isothiocyanatePhotoluminescenceCells CulturedImmunoassayB-LymphocytesLeukemiaNanotubesCluster of differentiationmedicine.diagnostic_testbiology010401 analytical chemistryhemic and immune systemsВ-lymphoblast cells021001 nanoscience & nanotechnologyFlow CytometryMolecular biologyhumanities0104 chemical scienceschemistryCell cultureCancer cell:NATURAL SCIENCES [Research Subject Categories]biology.proteinAntibodyZinc Oxide0210 nano-technologyhuman activitiesBiomarkersTalanta
researchProduct

Regulatory T Cells and IL-10 Independently Counterregulate Cytotoxic T Lymphocyte Responses Induced by Transcutaneous Immunization

2011

Background: The imidazoquinoline derivate imiquimod induces inflammatory responses and protection against transplanted tumors when applied to the skin in combination with a cognate peptide epitope (transcutaneous immunization, TCI). Here we investigated the role of regulatory T cells (Treg) and the suppressive cytokine IL-10 in restricting TCI-induced cytotoxic T lymphocyte (CTL) responses. Methodology/Principal Findings: TCI was performed with an ointment containing the TLR7 agonist imiquimod and a CTL epitope was applied to the depilated back skin of C57BL/6 mice. Using specific antibodies and FoxP3-diphteria toxin receptor transgenic (DEREG) mice, we interrogated inhibiting factors after…

Mouselcsh:MedicineEpitopes T-LymphocyteAdaptive ImmunityT-Lymphocytes RegulatoryImmune toleranceMiceMedicineCytotoxic T celllcsh:ScienceImmune ResponseSkinMice KnockoutB-LymphocytesMultidisciplinaryImiquimodFOXP3hemic and immune systemsForkhead Transcription FactorsAnimal ModelsFlow CytometryInterleukin-10Interleukin 10medicine.anatomical_structureAminoquinolinesCytokinesIntercellular Signaling Peptides and ProteinsImmunotherapyResearch ArticleHeparin-binding EGF-like Growth FactorT cellImmune CellsImmunologychemical and pharmacologic phenomenaImmune SuppressionImmunomodulationImmune systemModel OrganismsImmune ToleranceAnimalsBiologyB cellbusiness.industrylcsh:RImmunityMice Inbred C57BLCTL*Immune SystemImmunologyImmunologic Techniqueslcsh:QImmunizationbusinessT-Lymphocytes CytotoxicPLoS ONE
researchProduct

Friend retrovirus infection of myeloid dendritic cells impairs maturation, prolongs contact to naïve T cells, and favors expansion of regulatory T ce…

2007

AbstractRetroviruses have developed immunmodulatory mechanisms to avoid being attacked by the immune system. The mechanisms of this retrovirus-associated immune suppression are far from clarified. Dendritic cells (DCs) have been attributed a decisive role in these pathogenic processes. We have used the Friend retrovirus (FV) mouse model in order to acquire further knowledge about the role of infection of DCs in virus-induced immunosuppression. About 20% of the myeloid DCs that were generated from the bone marrow of FV-infected mice carried FV proteins. The infection was productive, and infected DCs transmitted the virus in cell culture and in vivo. FV infection of DCs led to a defect in DC …

MyeloidImmunologyPopulationMedizinBone Marrow CellsMice Transgenicchemical and pharmacologic phenomenaCell CommunicationBiologyLymphocyte ActivationT-Lymphocytes RegulatoryBiochemistryMiceImmune systemAntigenImmune TolerancemedicineAnimalsCytotoxic T cellMyeloid CellseducationCell ProliferationAntigen PresentationMice Inbred BALB Ceducation.field_of_studyFollicular dendritic cellsModels ImmunologicalFOXP3hemic and immune systemsDendritic CellsCell BiologyHematologyFriend murine leukemia virusCell biologymedicine.anatomical_structureImmunologyBone marrowRetroviridae InfectionsBlood
researchProduct

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

2022

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ADA can only be observed post randomization, and imbalances in baseline prognostic factors can confound the interpretation of ADA impact. We applied methodology to account for the confoundin…

Oncologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRandomizationCombination therapyDatabases FactualMEDLINERM1-950Antibodies Monoclonal HumanizedGeneral Biochemistry Genetics and Molecular BiologyArticleAtezolizumabimmune system diseasesInternal medicineNeoplasmsmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAdverse effectImmune Checkpoint InhibitorsClinical Trials as Topicbusiness.industryGeneral NeuroscienceImmunogenicityResearchConfoundingnutritional and metabolic diseaseshemic and immune systemsGeneral MedicineArticlesAntibodies Monoclonal Humanized/immunology; Antibodies Monoclonal Humanized/pharmacokinetics; Antibodies Neutralizing/immunology; Antibodies Neutralizing/metabolism; Clinical Trials as Topic; Databases Factual; Humans; Immune Checkpoint Inhibitors/immunology; Immune Checkpoint Inhibitors/pharmacokinetics; Neoplasms/drug therapy; Safety; Treatment OutcomeAntibodies NeutralizingClinical trialenzymes and coenzymes (carbohydrates)Treatment OutcomeTherapeutics. PharmacologyPublic aspects of medicineRA1-1270SafetybusinessClinical and translational science
researchProduct